DK3943070T3 - Langtidsvirkende formuleringer af bedaquilin - Google Patents
Langtidsvirkende formuleringer af bedaquilin Download PDFInfo
- Publication number
- DK3943070T3 DK3943070T3 DK21178526.6T DK21178526T DK3943070T3 DK 3943070 T3 DK3943070 T3 DK 3943070T3 DK 21178526 T DK21178526 T DK 21178526T DK 3943070 T3 DK3943070 T3 DK 3943070T3
- Authority
- DK
- Denmark
- Prior art keywords
- bedaquilin
- long
- acting formulations
- formulations
- acting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17181354 | 2017-07-14 | ||
EP18167463 | 2018-04-16 | ||
EP18739856.5A EP3651736B1 (en) | 2017-07-14 | 2018-07-13 | Long-acting formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3943070T3 true DK3943070T3 (da) | 2024-01-22 |
Family
ID=62874924
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18739856.5T DK3651736T3 (da) | 2017-07-14 | 2018-07-13 | Langtidsvirkende formuleringer |
DK21178526.6T DK3943070T3 (da) | 2017-07-14 | 2018-07-13 | Langtidsvirkende formuleringer af bedaquilin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18739856.5T DK3651736T3 (da) | 2017-07-14 | 2018-07-13 | Langtidsvirkende formuleringer |
Country Status (28)
Country | Link |
---|---|
US (2) | US11141384B2 (da) |
EP (3) | EP3943070B1 (da) |
JP (3) | JP7102500B2 (da) |
KR (2) | KR102679979B1 (da) |
CN (2) | CN110869004B (da) |
AU (1) | AU2018298855B2 (da) |
BR (1) | BR112020000687A2 (da) |
CA (1) | CA3069069A1 (da) |
CO (1) | CO2020000328A2 (da) |
CY (1) | CY1124782T1 (da) |
DK (2) | DK3651736T3 (da) |
ES (2) | ES2891976T3 (da) |
FI (1) | FI3943070T3 (da) |
HR (2) | HRP20211450T1 (da) |
HU (2) | HUE064651T2 (da) |
JO (1) | JOP20200004B1 (da) |
LT (2) | LT3943070T (da) |
MD (1) | MD3651736T2 (da) |
PE (1) | PE20200336A1 (da) |
PH (1) | PH12020500076A1 (da) |
PL (2) | PL3651736T3 (da) |
RS (2) | RS65207B1 (da) |
SA (1) | SA520410975B1 (da) |
SI (2) | SI3651736T1 (da) |
SM (2) | SMT202100557T1 (da) |
UA (1) | UA126403C2 (da) |
WO (1) | WO2019012100A1 (da) |
ZA (1) | ZA202000215B (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3943070T (lt) | 2017-07-14 | 2024-02-12 | Janssen Pharmaceutica Nv | Ilgo veikimo bedakvilino preparatai |
WO2020123336A1 (en) * | 2018-12-13 | 2020-06-18 | Qrumpharma Inc. | Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them |
JP2023532982A (ja) | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 長時間作用型配合物 |
MX2023000439A (es) * | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
JP2023532981A (ja) * | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 長時間作用型配合物 |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
TW202423427A (zh) | 2022-09-28 | 2024-06-16 | 比利時商健生藥品公司 | 長效配方 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US6495534B2 (en) | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
PT1527050E (pt) * | 2002-07-25 | 2010-06-22 | Janssen Pharmaceutica Nv | Derivados de quinolina e sua utilização como inibidores de micobactérias |
EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
ME01445B (me) | 2005-05-25 | 2013-12-20 | Janssen Pharmaceutica Nv | PROCES ZA PRIPREMU (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETIL]-2-METOKSI-ALF A-l-NAFTALENIL-BETA-FENIL-3-KINOLINETANOLA |
HUE038797T2 (hu) | 2006-06-23 | 2018-11-28 | Janssen Sciences Ireland Uc | TMC278 vizes szuszpenziói |
UA97813C2 (uk) | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
US9421194B2 (en) | 2010-04-05 | 2016-08-23 | Rutgers, The State University Of New Jersey | Lung targeting dual drug delivery system |
TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
SI2696848T1 (sl) | 2011-04-15 | 2020-10-30 | Janssen Pharmaceutica N.V. | Liofilizirane zdravilne nanosuspenzije |
WO2016022853A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
US20180000810A1 (en) * | 2015-01-27 | 2018-01-04 | Janssen Pharmaceutica Nv | Dispersible compositions |
US10653679B2 (en) * | 2015-05-04 | 2020-05-19 | Board Of Trustees Of Michigan State University | Compositions and methods for inhibiting bacterial growth |
ES2972618T3 (es) | 2015-10-14 | 2024-06-13 | The Global Alliance For Tb Drug Dev Inc | Composición antibacteriana de combinación y régimen antibacteriano de corta duración que comprende linezolid, bedaquilina y pretomanida |
CN108349898B (zh) * | 2015-10-20 | 2021-03-23 | 浙江海正药业股份有限公司 | 富马酸贝达喹啉的晶型及其制备方法 |
EP3634583A4 (en) | 2017-06-06 | 2021-03-03 | Merck Sharp & Dohme Corp. | Long-action implant for treatment of infectious diseases |
LT3943070T (lt) | 2017-07-14 | 2024-02-12 | Janssen Pharmaceutica Nv | Ilgo veikimo bedakvilino preparatai |
JP2023532981A (ja) | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 長時間作用型配合物 |
MX2023000439A (es) | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
JP2023532982A (ja) | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 長時間作用型配合物 |
-
2018
- 2018-07-13 LT LTEP21178526.6T patent/LT3943070T/lt unknown
- 2018-07-13 JP JP2020501137A patent/JP7102500B2/ja active Active
- 2018-07-13 SI SI201830409T patent/SI3651736T1/sl unknown
- 2018-07-13 WO PCT/EP2018/069066 patent/WO2019012100A1/en active Application Filing
- 2018-07-13 DK DK18739856.5T patent/DK3651736T3/da active
- 2018-07-13 ES ES18739856T patent/ES2891976T3/es active Active
- 2018-07-13 FI FIEP21178526.6T patent/FI3943070T3/fi active
- 2018-07-13 SM SM20210557T patent/SMT202100557T1/it unknown
- 2018-07-13 HU HUE21178526A patent/HUE064651T2/hu unknown
- 2018-07-13 LT LTEPPCT/EP2018/069066T patent/LT3651736T/lt unknown
- 2018-07-13 UA UAA202000901A patent/UA126403C2/uk unknown
- 2018-07-13 HR HRP20211450TT patent/HRP20211450T1/hr unknown
- 2018-07-13 HU HUE18739856A patent/HUE055762T2/hu unknown
- 2018-07-13 CN CN201880046696.8A patent/CN110869004B/zh active Active
- 2018-07-13 RS RS20240102A patent/RS65207B1/sr unknown
- 2018-07-13 EP EP21178526.6A patent/EP3943070B1/en active Active
- 2018-07-13 HR HRP20240058TT patent/HRP20240058T1/hr unknown
- 2018-07-13 CA CA3069069A patent/CA3069069A1/en active Pending
- 2018-07-13 JO JOP/2020/0004A patent/JOP20200004B1/ar active
- 2018-07-13 US US16/630,676 patent/US11141384B2/en active Active
- 2018-07-13 KR KR1020207003364A patent/KR102679979B1/ko active Active
- 2018-07-13 RS RS20211178A patent/RS62362B1/sr unknown
- 2018-07-13 SI SI201930692T patent/SI3943070T1/sl unknown
- 2018-07-13 AU AU2018298855A patent/AU2018298855B2/en active Active
- 2018-07-13 DK DK21178526.6T patent/DK3943070T3/da active
- 2018-07-13 EP EP23206129.1A patent/EP4356968A3/en active Pending
- 2018-07-13 PL PL18739856T patent/PL3651736T3/pl unknown
- 2018-07-13 MD MDE20200530T patent/MD3651736T2/ro unknown
- 2018-07-13 PE PE2020000033A patent/PE20200336A1/es unknown
- 2018-07-13 SM SM20240033T patent/SMT202400033T1/it unknown
- 2018-07-13 KR KR1020247021329A patent/KR20240108542A/ko active Pending
- 2018-07-13 EP EP18739856.5A patent/EP3651736B1/en active Active
- 2018-07-13 ES ES21178526T patent/ES2970801T3/es active Active
- 2018-07-13 CN CN202210671005.1A patent/CN115252548A/zh active Pending
- 2018-07-13 BR BR112020000687-4A patent/BR112020000687A2/pt unknown
- 2018-07-13 PL PL21178526.6T patent/PL3943070T3/pl unknown
-
2020
- 2020-01-06 SA SA520410975A patent/SA520410975B1/ar unknown
- 2020-01-09 PH PH12020500076A patent/PH12020500076A1/en unknown
- 2020-01-13 ZA ZA2020/00215A patent/ZA202000215B/en unknown
- 2020-01-14 CO CONC2020/0000328A patent/CO2020000328A2/es unknown
-
2021
- 2021-09-08 US US17/469,021 patent/US12171887B2/en active Active
- 2021-09-23 CY CY20211100837T patent/CY1124782T1/el unknown
-
2022
- 2022-07-06 JP JP2022108846A patent/JP7441276B2/ja active Active
-
2023
- 2023-12-22 JP JP2023216574A patent/JP7620692B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
DK3688162T3 (da) | Formuleringer | |
DK3377059T3 (da) | Hæmmere af cxcr2 | |
DK3943070T3 (da) | Langtidsvirkende formuleringer af bedaquilin | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3116533T3 (da) | Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser | |
DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
DK3368014T3 (da) | Nye formuleringer af cannabinoider | |
DK3302437T3 (da) | Stabile cannabinoidformuleringer | |
DK3185853T3 (da) | Inhalerbare pulverformuleringer af alginatoligomerer | |
EP3442586A4 (en) | STABLE PARENTERAL NIMOPIDINE FORMULATION | |
DK3798222T3 (da) | Krystallinsk form af den frie base af lorlatinib | |
DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
DK3285756T3 (da) | Formuleringer af l-ornithinphenylacetat | |
DK3457851T3 (da) | Derivater af sobetirom | |
DK3261608T5 (da) | Sammensætninger omfattende kombinationer af organiske syrer | |
EP3364945C0 (en) | SOLID FORMULATION | |
DK3220891T3 (da) | Sublingual formulering af riluzol | |
DK3678644T3 (da) | Formuleringer af copanlisib | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3697418T3 (da) | Forbedrede formuleringer af bromocriptin | |
DK3511000T3 (da) | Krystallinsk form x2 af grapiprant | |
DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
DK3310331T3 (da) | Injicerbare farmaceutiske formuleringer af lefamulin |